Makers of Tasigna Leukemia Drug Lawsuit

Novartis AG makers of Tasigna leukemia drug failed to warn US doctors and patients of the potential to develop atherosclerosis

Friday, June 9, 2017 - Novartis AG, makers of the leukemia drug Tasigna, has been sued by the estate of a California man in March of 2016. The lawsuit claims that the makers of the drug failed to warn US doctors and their patients of the potential for those taking the drug to develop atherosclerosis. According to www.webmd.com, "Atherosclerosis is a disease of the arteries characterized by the deposition of plaques of fatty material on their inner walls." Atherosclerosis is irreversible. The suit goes on to allege that the company knew of reports that the drug caused the disease since 2011.

Canada's health agency warned Canadian doctors of the drug's potentially deadly side effects in 2013, but the company did nothing to pass that information on to health officials in the United States. The warning stated that due to the atherosclerosis risks associated with Tasigna, patients taking the drug should be closely monitored for indications of arterial disease. In addition to the health warnings, product warning literature was updated with information about the drug's link to atherosclerosis.

As is often the case, the plaintiff was taking another medication without complications and was instructed by his physician to switch to Tasigna and then the symptoms of atherosclerosis began immediately. The original drug the plaintiff was taking was also sold by Novartis. Within a year of switching from one leukemia drug to Tasigna, the plaintiff underwent an angiogram, a standard test for those suffering the symptoms of heart disease. The results of the test indicated that the plaintiff was experiencing total blockage of the right femoral artery. The femoral artery " is the main artery that provides oxygenated blood to the tissues of the leg. It passes through the deep tissues of the femoral (or thigh) region of the leg parallel to the femur. The common femoral artery is the largest artery found in the femoral region of the body." (1) After changing drugs, the plaintiff died soon after of complications from atherosclerosis. Had the link between the deadly side effects of Tasigna and atherosclerosis been known, the plaintiff would have continued on his original medication.

The suit goes on to claim that the company's decision not to warn the hundreds of thousands of Tasigna users in the United States was part of a premeditated marketing strategy of Novartis designed to protect the company's income stream of tens of billions of dollars per year from the sale of the drug and to not tarnish their brand.

Zealous Advocates and Experienced Tasigna Lawyers

If you have a loved one who has died as a result of using the deadly leukemia drug Tasigna, you can sue Novartis for reimbursement of medical expenses, lost wages, and pain and suffering and other related wrongful death-related damages. The lawyers at the Onder Law firm represent the survivors of those who have died as a result of taking Tasigna as well as users of the drug that are suffering from the adverse side effect of atherosclerosis. The Onder Law firm operates on a contingency basis and there is no fee unless we win and collect so please make the call to us today.

More Recent Tasigna Atherosclerosis Lawsuit News:

• Tasigna Patients Are Warned of The Risk of Sudden Death | 5/13/2019
• Tasigna's Atherosclerosis Risk Is Well-Documented By Researchers For Peer-Reviewed Medical Publications | 5/8/2019
• Tasigna's Atherosclerosis Side Effect Is Not Forgotten | 4/17/2019
• Trying Tasigna As A Last Resort May Make Sense To Terminally Ill Cancer Patients | 4/12/2019
• Novartis Claim Tasigna Can Help Parkinson's Patients is Met With Skepticism | 4/4/2019
• Novartis Failed To Warn American Doctors Who In Turn Failed To Warn Patients of Tasigna's Atherosclerosis Risks | 3/20/2019
• Tasigna Is Being Repurposed To Treat Parkinson's Disease | 3/14/2019
• Some Patient Can Cease Taking Tasigna But They May Have Already Developed Atherosclerosis | 3/12/2019
• Health Experts Warn of Potentially Deadly Tasigna Drug Interactions | 3/5/2019
• The Potential To Someday Stop Tasigna Treatments Should Not Be An Incentive To Take The Drug | 2/28/2019
• Tasigna Studies Show The Drug Should Be Taken As A Last Resort | 2/24/2019
• Cancer Doctors and Medical Websites Should Take Tasigna's Atherosclerosis Risks More Seriously | 2/18/2019
• The FDA May Be Putting Children's Lives In Danger By Ignoring Tasigna's Atherosclerosis Risk | 2/12/2019
• The FDA May Have Overlooked Tasigna's Atherosclerosis Side Effect When Approving its Usage by Children | 2/5/2019
• Children With Cancer May Now Start Taking Tasigna | 1/31/2019
• Studies Reported by Leading Experts Focus on Tasigna Toxicity | 1/25/2019
• Novartis Has a History of Deceptive Sale Practices That Taints Their Credibility | 1/22/2019
• Novartis Changes Tasigna's Label But Not Its Toxicity | 1/16/2019
• Tasigna Doctors May Be Ignoring Atherosclerosis Risks | 1/11/2019
• Cancer Doctors Prescribing Tasigna Should Be Trained Like Heart Specialists | 1/8/2019
• Tasigna is Effective in Treating Chronic Myeloid Leukemia | 1/1/2019
• Early Warning Signs of Chronic Myeloid Leukemia (CML) | 12/5/2018
• CML Patients in Remission May Discontinue Taking Tasigna | 12/1/2018
• Tasigna's Atherosclerosis Warnings is Rarely Seen by Cancer Patients | 11/28/2018
• Novartis' Failure to Warn the FDA May Have Led to Atherosclerosis in As Many As One in Four Tasigna Patients | 11/12/2018
• Novartis Highlights Tasigna's Effectiveness yet Downplays The Drug's Deadly Side Effects | 11/8/2018
• Novartis Takes Advantage of Tasigna's Catch 22 | 10/30/2018
• Tasigna Atherosclerosis Ignored by Novartis Celebrity Spokesperson | 10/24/2018
• Oncologists May Be Ignoring the Cardiovascular Side Effects of Tasigna | 10/16/2018
• The FDA Atherosclerosis Warning Came Too Late for Tasigna Patients in the United States | 10/8/2018
• One-Third of Tasigna Patients Could Face Coronary Bypass Surgery | 10/4/2018
• Billion Dollar Fines Are Just a Cost of Doing Business For Novartis | 10/2/2018
• Cancer Patients Should View Novartis' New Tasigna Label With Scepticism | 9/28/2018
• Novartis Boasts of Tasigna's Effectiveness While Ignoring the Atherosclerosis Side Effects | 9/27/2018
• Tasigna May Be One Of The Most Deadly Drugs On The Market Today | 9/25/2018
• NBA Star's Arterial Blockage May Have Been Caused by Taking Tasigna | 9/22/2018
• Taxpayers Saved Billions By Novartis AG Whistleblower | 9/20/2018
• Tasigna Carries The Unacceptable Risk of Developing Atherosclerosis and Amputation | 9/19/2018
• Tasigna's Cancer-Fighting Success May Be Tempered By The Risk Of Sudden Death | 9/17/2018
• Novartis Pulled No Punches In Warning Canadians About The Atherosclerosis Related Side effects Of Tasigna Yet Said Nothing To Warn Cancer Patients In The United States. | 9/11/2018
• Novartis is a Repeat Offender for Fraudulent Drug Marketing | 8/29/2018
• Peripheral Artery Disease Plagues Tasigna Patients | 8/27/2018
• Patients Could Have Benefited From Gleevec's Generic Alternative | 8/21/2018
• Novartis/Tasigna Lawsuit May Seek Punitive Damages | 8/17/2018
• Tasigna Atherosclerosis Trial Set to Proceed | 8/14/2018
• Medical Websites Ignore Tasigna's Risks | 8/10/2018
• Novartis haste in rushing Tasigna to market has cost patients their lives | 8/8/2018
• Tasigna's Side Effects Require Special Attention From Prospective Patients | 8/6/2018
• Novartis Whistleblower Receives $12 Million For His Efforts | 7/31/2018
• Tasigna Atherosclerosis Hidden From Americans | 7/30/2018
• Gleevec Was a Cancer-Curing Miracle Drug | 7/26/2018
• Tasigna Stroke Victim's Trial to Proceed in Florida | 7/24/2018
• Novartis Employee Blows Whistle on Tasigna Fraud and Others | 7/20/2018
• Tasigna Side Effects Are Worse Than Cancer | 7/18/2018
• Tasigna Cancer Medication Carries More Risks Than Others | 7/11/2018
• Specialty Pharmacists Bribed to Prescribe Tasigna | 7/6/2018
• Novartis Billion-Dollar Fine for Fraudulent Marketing Tactics | 7/2/2018
• Tasigna Black Box Warning Addendum | 6/29/2018
• Tasigna Replaced Gleevec and Patients Suffered | 6/25/2018
• Specialty Pharmacists Selling Tasigna Compromised Ethical Standards | 6/20/2018
• US Department of Justice Fines Novartis One Billion Dollars | 6/13/2018
• Tasigna Sudden Death Warning | 6/11/2018
• Tasigna Cancer Treatment Poses Scary Risks | 6/7/2018
• Novartis Fraudulent Marketing Deception | 5/29/2018
• Tasigna Atherosclerosis Warning Never Made it to the US | 5/25/2018
• Novartis Tasigna Anti-Cancer Drug Has Side Effects That Include Sudden Death | 5/22/2018
• Tasigna Replaced Gleevec Under Fraudulent Circumstance | 5/18/2018
• Novartis Held Accountable For Concealing Tasigna Atherosclerosis Risk | 5/15/2018
• Tasigna Chemotherapy Carries a Sudden Death Warning | 5/10/2018
• Novartis Warns That Tasigna Can Cause Atherosclerosis | 5/6/2018
• Tasigna Poses Atherosclerosis Amputations Risk | 5/3/2018
• Tasigna Rushed to Market to Replace Gleevec | 12/29/2017
• Whistleblower Saves American Taxpayers Millions | 12/22/2017
• Gleevec-the Novartis AG Wonder Drug | 12/20/2017
• Tasigna Warnings | 12/18/2017
• Tasignas Black Box Warning Links The Drug To Atherosclerosis | 12/15/2017
• Novartis Fails To Warn The U.S. Medical Community About The Side Effects of Tasigna | 12/11/2017
• Tasigna Replaces Gleevec as the Novartis AGs Signature Anti-Cancer Chemotherapy Drug | 12/6/2017
• The Unmistakable Signs of Peripheral Artery Disease | 12/1/2017
• Whistleblower Causes Public Alert to Tasigna Side Effects | 11/27/2017
• The Estate of a California Man is Suing Novartis | 11/20/2017
• Ex-Novartis Salesmanager Blows The Whistle On Illegal Drug Marketing | 11/13/2017
• U.S. Cancer Patients Receive Tasigna Atherosclerosis Warning | 11/6/2017
• Novartis Marketed Tasigna to Replace Gleevec | 11/3/2017
• Leukemia Patients May Suffer From Heart Disease as Well | 10/30/2017
• Novartis' Potentially Misleading Drug Marketing Campaign | 10/23/2017
• Health Canada Issued a Tasigna Health Warning In 2013 | 10/16/2017
• Lawsuits Allege Novartis Was Aware of The Side Effects of Tasigna Yet Failed to Warn The American Public | 10/9/2017
• Tasigna Chemotherapy Atherosclerosis-related Side Effects | 10/2/2017
• The Onder Law Firm Seeks to Hold Novartis Accountable for the Suffering Tasigna Has Caused Families | 9/29/2017
• Novartis Fails to Warn About Tasigna Atherosclerosis | 9/22/2017
• Side Effects of Tasigna Cancer Drug Include Atherosclerosis and Peripheral Artery Disease | 9/15/2017
• Novartis Put Profits Ahead of Patients | 9/7/2017
• Novartis Failed to Warn the American Medical Community of the Side Effects of Tasigna | 9/1/2017
• Atherosclerosis Linked to Tasigna Anti Cancer Drug | 8/18/2017
• You Can Sue Novartis If You Have Developed Atherosclerosis-Related Conditions After Taking Tasigna | 8/11/2017
• Who Can Be Considered A Tasigna Victim | 8/4/2017
• Novartis AG makers of Tasigna Failed to Warn Public of the Dangerous Side Effects | 7/14/2017
• Tasigna Anti Cancer Drug Lawsuit | 7/7/2017
• Tasigna Drug Warning for Peripheral Arterial Disease | 6/30/2017
• Tasigna Cancer Treatment Drug Lawsuit | 6/26/2017
• Novartis International AG Lawsuits | 6/23/2017
• Lawsuits Against Novartis International AG Makers of Tasigna | 6/21/2017
• Tasigna Peripheral Artery Disease Warning | 6/19/2017
• Tasigna Lawsuits Against Drug Makers Novartis | 6/16/2017
• Atherosclerosis of the Aorta Linked to Tasigna Anti-Cancer Drug | 6/12/2017
• Tasigna a Cancer Drug Treatment | 6/5/2017
• Tasigna Peripheral Arterial Disease | 6/1/2017

Lawyers for Tasigna Atherosclerosis Lawsuits

Attorneys handling Tasigna lawsuits for leukemia, non-Hodgkin lymphoma, and multiple myeloma offer free, no-obligation case review for individuals and families who believe they may have grounds to file a Tasigna lawsuit. Working on a contingency basis, these attorneys are committed to never charging legal fees unless they win compensation in your Tasigna lawsuit. The product liability litigators handling Roundup claims at the Onder Law Firm have a strong track record of success in representing families harmed by dangerous drugs and consumer products.